Finance and plantation stocks were among the major gainers while the pharmaceutical and glove counters enjoyed strong interests, benefiting from the outbreak of the Influenza A (H1N1) epidemic.
The FTSE Bursa Malaysia Kuala Lumpur Composite Index (FBM KLCI) rose 11.65 points to 1,190.39 after trading at intra-day low of 1,178.74. The key index had opened 1.51 points higher at 1,180.25 yesterday morning.
The FBMEmas surged 78.32 points to 8,026.55, the FBM Top 100 went up 75.40 points to 7,804.76, the FBM70 increased 72.45 points to 7,900.93 and the FBM Ace Index was 9.21 points higher at 4,141.38.
The FBMEmas surged 78.32 points to 8,026.55, the FBM Top 100 went up 75.40 points to 7,804.76, the FBM70 increased 72.45 points to 7,900.93 and the FBM Ace Index was 9.21 points higher at 4,141.38.
The Finance Index climbed 105.51 points to 9,632.20, the Industrial Index gained 21.23 points to 2,607.54 and the Plantation Index advanced 44.95 points to 5,832.89.
Gainers outnumbered losers by 467 to 213 while 214 counters were unchanged and 360 others untraded. A total turnover of 708.738 million shares worth RM1.073 billion were transacted yesterday, up from Friday’s 609.163 million units worth RM1.075 billion.
Gainers outnumbered losers by 467 to 213 while 214 counters were unchanged and 360 others untraded. A total turnover of 708.738 million shares worth RM1.073 billion were transacted yesterday, up from Friday’s 609.163 million units worth RM1.075 billion.
Overall, the market remained bullish, with the FBM KLCI expected to re-test 1,200 points level after the adequate correction last week, an analyst said.
“The key index could certainly continue its advance, but the risk of a
pullback increases when securities are overbought , ” he said, adding that longterm traders must buy with a wide stoploss to tolerate unexpected pullback.
pullback increases when securities are overbought , ” he said, adding that longterm traders must buy with a wide stoploss to tolerate unexpected pullback.
CCM Duopharma Biotech gained 9 sen to RM2.57. The company has submitted a RM60 million tender to the Health Ministry to supply Omiflu antiviral drug to treat influenza-related diseases.
No comments:
Post a Comment